Source: https://peakpeptides.com/peptides/glow/ Peptide library · Blend # GLOW GLOW is a name used for mixtures containing GHK-Cu, BPC-157 and TB-500, not the many skincare products that use the word glow. The name does not establish a standardized formulation. Last reviewed September 22, 2026 At a glance - **Also called:** GLOW peptide; GLOW blend; GHK-Cu/BPC-157/TB-500 blend - **What it is:** A name used for three-component mixtures - **Evidence:** No blend trials; mostly component cells and animals - **FDA status:** Not FDA-approved for any use - **In sport:** Contains WADA-prohibited BPC-157 and TB-500 - **At Promise Peptides:** Listed; currently waitlist-only The short version Here, GLOW refers to mixtures containing GHK-Cu, BPC-157 and TB-500. It is not a face cream, serum or other skincare item that happens to use the same word. No controlled study has tested the three-component blend. Research instead examines each ingredient alone, often in cells, rats or topical models. GLOW is not FDA-approved. Its components have separate evidence gaps and compounding histories, and mixing them does not create approval. Promise currently lists the blend for waitlist sign-ups. ## What it is GLOW is a mixture of three distinct substances. GHK-Cu is the copper complex of the tripeptide Gly-His-Lys. BPC-157 is a synthetic 15-amino-acid peptide. TB-500 is Ac-LKKTETQ, a seven-amino-acid fragment associated with full-length thymosin beta-4. They are co-formulated but do not become a new molecule or share one chemical identity. GLOW therefore has no single amino-acid sequence, formula, molecular weight or CAS number. Formulation ratios are not standardized across all uses of the name. The evidence gap starts with that identity problem: research on a topical GHK-Cu cosmetic, isolated BPC-157 or full-length thymosin beta-4 does not test an injectable three-part formulation. ## Where the research stands The complete blend has not climbed the evidence ladder. The component literature provides biological hypotheses, not proof that the mixture is stable, safe, synergistic or effective. Every card below names the single component or parent protein actually studied. How far the evidence has climbed 1. Cell studies · None · No complete-blend cell study 2. Animal studies · None · Components studied separately 3. Small human pilots · None · No GLOW pilot identified 4. Controlled human trials · None · No controlled GLOW trial 5. FDA approval · No · No approved GLOW product Here is what selected component studies looked at. Each names its model because none tested GLOW itself. - **GHK-Cu alone: collagen cells** (Human cells · 1988): GHK-Cu was studied in cultured human fibroblasts, where researchers measured collagen synthesis. It was not injected into people and was not combined with the other ingredients.[1] - **BPC-157 alone: rat tendons** (Rats · Cells · 2003): A rat Achilles-tendon model and rat tendon-cell culture measured mechanical, microscopic and cell-growth changes after BPC-157. GLOW was not used.[2] - **BPC-157 alone: vessel signaling** (Animals · Human cells · 2017): Human vascular cells, a chick membrane and a rat blood-flow model were used to measure VEGFR2 signaling and blood-vessel formation. The study did not test GLOW or a human treatment.[3] - **Full protein: wound model** (Rats · 1999): Full-length thymosin beta-4 was tested in rat skin wounds, with measurements of re-epithelialization, contraction, collagen and angiogenesis. The short TB-500 fragment and GLOW were not tested.[4] - **BPC-157 human gap** (Review · 2025): A review found only three small human BPC-157 pilots and no rigorous large-scale trials. Even that limited evidence concerned BPC-157 alone, not GLOW.[5] - **Unapproved peptides review** (Review · 2026): A sports-medicine review assessed safety evidence for unapproved peptides including these components. It did not identify human safety evidence for GLOW as a blend.[6] ## What the research can’t tell you - **The injectable blend is untested**: No study establishes safety, stability, pharmacokinetics or outcomes for all three ingredients together. - **The GHK-Cu study was cellular**: The cited GHK-Cu paper measured collagen synthesis in cultured human fibroblasts. It did not test a topical product, injection or the GLOW blend.[1] - **Full protein is not TB-500**: Most thymosin beta-4 efficacy work used the full 43-amino-acid protein. TB-500 is the much shorter Ac-LKKTETQ fragment, so direct transfer is not justified.[4] - **Synergy has not been shown**: Overlapping repair-related pathways do not prove that a mixture is stronger or safer. Combination effects could also be neutral or adverse. - **Angiogenesis creates a theoretical question**: BPC-157 and full-length thymosin beta-4 studies include new blood-vessel formation. Tumor concern is reasoning from mechanism, not a finding in people using GLOW.[3] - **Anti-doping rules apply**: WADA prohibits BPC-157 and names TB-500 among thymosin beta-4 derivatives prohibited at all times.[7] ## FDA status Not FDA-approved for any use No FDA-approved GLOW combination exists. A compounded blend remains unapproved, and FDA does not verify a compounded drug’s safety, effectiveness or quality before marketing.[8] FDA’s page, content current as of April 22, 2026, lists BPC-157, injectable GHK-Cu and the thymosin beta-4 fragment identified as TB-500 in its withdrawn-nomination table. FDA retains safety notes next to the entries. Withdrawal does not change the other requirements that apply to compounding.[9] None is on FDA’s finalized list of additional bulk substances for patient-specific compounding.[10] Promise Peptides is currently taking waitlist sign-ups. Joining is not a medical request and no prescription comes from it. ## A prescription route Promise is currently accepting waitlist signups. Joining is not a treatment request and does not result in a prescription. If treatment visits open, any treatment request would require clinical review; prescribing and pharmacy fulfillment would remain separate decisions. 1. **Start on Promise’s GLOW page**: It shows what the treatment involves and its current availability. 2. **Answer the GLOW questionnaire**: A licensed provider reviews health history, medicines and goals, and can decline. Not everyone qualifies. 3. **Pharmacy review is a separate step**: A prescription does not guarantee preparation or dispensing. A pharmacy must separately determine whether it can fulfill the prescription under the applicable requirements. A prescription does not make GLOW FDA-approved or turn separate component findings into evidence for the blend; it reflects a clinician’s review of an individual case. GLOW at Promise Read the treatment information and view the current waitlist. [Join the Promise waitlist](https://mypromise.com/products/glow?utm_source=peak&utm_medium=affiliate&utm_campaign=library&utm_content=glow) Peak may earn money when readers become Promise patients. Joining does not guarantee future treatment availability. Availability would depend on the treatment, state, clinical review and separate pharmacy review. ## Questions ### What peptides are in the GLOW blend? The name is used for mixtures containing GHK-Cu, BPC-157 and TB-500. They remain three chemically distinct substances. ### Are there human studies on GLOW? No controlled human study of the blend is identified in the cited research. Limited human evidence for individual components cannot be presented as a GLOW result.[5] ### How is GLOW different from KLOW? KLOW adds KPV to the same three named components. No controlled study establishes what that added component changes. ## Sources 1. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. *FEBS Lett*. 1988;238:343-346. [PubMed 3169264](https://pubmed.ncbi.nlm.nih.gov/3169264/) 2. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. *J Orthop Res*. 2003;21:976-983. [PubMed 14554208](https://pubmed.ncbi.nlm.nih.gov/14554208/) 3. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. *J Mol Med*. 2017;95:323-333. [PubMed 27847966](https://pubmed.ncbi.nlm.nih.gov/27847966/) 4. Malinda KM, et al. Thymosin beta4 accelerates wound healing. *J Invest Dermatol*. 1999. [PubMed 10469335](https://pubmed.ncbi.nlm.nih.gov/10469335/) 5. McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. *Curr Rev Musculoskelet Med*. 2025. [PubMed 40789979](https://pubmed.ncbi.nlm.nih.gov/40789979/) 6. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. *Sports Med*. 2026. [PubMed 41966639](https://pubmed.ncbi.nlm.nih.gov/41966639/) 7. World Anti-Doping Agency. [The 2026 Prohibited List](https://www.wada-ama.org/en/prohibited-list) (S0 and S2.3). 8. U.S. Food and Drug Administration. [Compounding and the FDA: Questions and Answers](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers). 9. U.S. Food and Drug Administration. [Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks). Content current as of April 22, 2026. 10. U.S. Food and Drug Administration. [Bulk drug substances used in compounding under section 503A of the FD&C Act](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act). ## Also in the library - [KLOW](https://peakpeptides.com/peptides/klow/) (Blend) - [GHK-Cu](https://peakpeptides.com/peptides/ghk-cu/) (Copper tripeptide) - [BPC-157](https://peakpeptides.com/peptides/bpc-157/) (Synthetic peptide) - [TB-500](https://peakpeptides.com/peptides/tb-500/) (Synthetic peptide) --- Peak maps the terrain; it does not examine anyone, so nothing here is medical advice, and the decision about any treatment belongs to a licensed provider who has reviewed your health. Peak may earn money when readers become Promise patients. Peak is not affiliated with any company called Peak Peptides or Peak Performance Peptides.